Neuren Pharmaceuticals Ltd has released a press release.
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Story so far
Earlier from Neuren Pharmaceuticals
- Acadia submits Rett Syndrome New Drug Application to the FDA
- Neuren commences Phase 2 trial of NNZ-2591 in Angelman
- Neuren appoints Chief Medical Officer in United States
- FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial
- FDA approval for Phelan-McDermid IND and Phase 2 trial
Later from Neuren Pharmaceuticals
- Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS
- S&P DJI Announces September 2022 Quarterly Rebalance
- Rett Syndrome NDA accepted for Priority Review by FDA
- Neuren receives US$10 million milestone payment
- Q3 2022 quarterly activity and cash flow report
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals